Sino Biopharmaceutical’s Breakthrough in NSCLC Treatment at 2025 ASCO Meeting

Sino Biopharmaceutical ( (HK:1177) ) has provided an update.

Sino Biopharmaceutical has announced the results of its phase III clinical study for benmelstobart injection, with or without anlotinib, as a maintenance treatment for non-small cell lung cancer (NSCLC) at the 2025 ASCO Annual Meeting. The study demonstrated a significant extension in median progression-free survival for patients receiving the combination treatment, marking a potential shift in clinical practice guidelines and offering new hope for NSCLC patients. The study’s findings have led to the acceptance of a marketing application for the new indication by the National Medical Products Administration of China, highlighting the potential impact on the company’s operations and industry positioning.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$5.10 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. The company, along with its subsidiaries, is involved in the development and commercialization of pharmaceutical products, with a market focus on innovative treatments for various diseases, including cancer.

Average Trading Volume: 106,012,427

Technical Sentiment Signal: Buy

Current Market Cap: HK$78.69B

For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.